Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, BioTek Collaborate on Tech Validation Program

NEW YORK (GenomeWeb News) – Invitrogen and BioTek Instruments are collaborating to validate the compatibility of their technologies, and they plan to continue to develop and promote joint applications for the drug discovery market, the microplate and software maker BioTek said today.
 
Under the collaboration, the companies have validated the compatibility of Invitrogen’s reagents and other technologies with BioTek’s microplate detection tools. So far, the companies have validated five Invitrogen drug discovery products with BioTex’s 4 Multi-Mode Microplate Reader including: the GeneBlazer; LanthaScreen, Adapta Universal Kinase Assay; the Z-Lyte; and the Omnia.
 
Invitrogen also has certified BioTek’s Synergy 2 Multi-Mode Microplate Readers for use with its LanthaScreen kinase and nuclear hormone receptor technology.
 
“Through this partnership, drug discovery researchers will be able to obtain integrated instrumentation and reagent solutions, thereby removing the frustration of discovering that the biological assay system they have chosen is not compatible with the instrumentation,” John Printen, director of Invitrogen’s cell signaling business segment, said in a statement.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.